EDIT vs. TSHA, CCCC, TRML, ALEC, EXAI, REPL, VYGR, FATE, MESO, and OCGN
Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Taysha Gene Therapies (TSHA), C4 Therapeutics (CCCC), Tourmaline Bio (TRML), Alector (ALEC), Exscientia (EXAI), Replimune Group (REPL), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Mesoblast (MESO), and Ocugen (OCGN). These companies are all part of the "biological products, except diagnostic" industry.
Taysha Gene Therapies (NASDAQ:TSHA) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
Editas Medicine received 218 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 72.81% of users gave Taysha Gene Therapies an outperform vote while only 54.04% of users gave Editas Medicine an outperform vote.
In the previous week, Taysha Gene Therapies had 4 more articles in the media than Editas Medicine. MarketBeat recorded 7 mentions for Taysha Gene Therapies and 3 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.48 beat Taysha Gene Therapies' score of 0.44 indicating that Taysha Gene Therapies is being referred to more favorably in the media.
Taysha Gene Therapies presently has a consensus target price of $6.88, suggesting a potential upside of 185.27%. Editas Medicine has a consensus target price of $15.00, suggesting a potential upside of 170.27%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Taysha Gene Therapies is more favorable than Editas Medicine.
Taysha Gene Therapies has higher earnings, but lower revenue than Editas Medicine. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Taysha Gene Therapies has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.
77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 2.3% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 2.2% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Editas Medicine has a net margin of -196.12% compared to Editas Medicine's net margin of -722.06%. Editas Medicine's return on equity of 0.00% beat Taysha Gene Therapies' return on equity.
Summary
Taysha Gene Therapies beats Editas Medicine on 12 of the 18 factors compared between the two stocks.
Get Editas Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Editas Medicine Competitors List
Related Companies and Tools
